Arvinas logo
Close this search box.

– Bavdegalutamide demonstrated a 46% PSA 50 rate in patients with metastatic castration-resistant prostate cancer (mCRPC) and androgen receptor (AR) T878X/H875Y tumor mutations – – Arvinas plans to initiate a pivotal trial by year end 2022 evaluating bavdegalutamide in patients with mCRPC who have


You are now leaving Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

Skip to content